BCD-131
Phase 3Biologic
BCD-131 is one of 47 biologic programs targeting Anemia. It is currently in Phase 3.
1
Indications
3
Total Trials
1
Active Trials
46
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
75 competitors in Anemia
#DrugCompanyPhaseTrials
1Epogen
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.Phase 3
Nipent
PfizerApproved
Leustatin
EMD SeronoApproved
Rayos
RRoxane Laboratories
Approved
Orgovyx
Sumitomo Pharma America, Inc.Approved
Rituxan
RochePhase 3
Cytoxan
BBaxter Healthcare Corporation
Phase 3
Campath
GGenzyme, a Sanofi Company
Phase 3
Revlimid
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Phase 3
Imbruvica
PPharmacyclics LLC.
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Anemia2 trials
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for BCD-131. EMBL-EBI & Wellcome Sanger Institute.
- [4]